RT Journal Article
SR Electronic
T1 First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in ex COVID-19 subjects
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252590
DO 10.1101/2021.03.05.21252590
A1 Mazzoni, Alessio
A1 Di Lauria, Nicoletta
A1 Maggi, Laura
A1 Salvati, Lorenzo
A1 Vanni, Anna
A1 Capone, Manuela
A1 Lamacchia, Giulia
A1 Mantengoli, Elisabetta
A1 Spinicci, Michele
A1 Zammarchi, Lorenzo
A1 Kiros, Seble Tekle
A1 Colao, Maria Grazia
A1 Parronchi, Paola
A1 Scaletti, Cristina
A1 Turco, Lucia
A1 Liotta, Francesco
A1 Rossolini, Gian Maria
A1 Cosmi, Lorenzo
A1 Bartoloni, Alessandro
A1 Annunziato, Francesco
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252590.abstract
AB Characterizing the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of two doses BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (ex COVID-19) compared to naïve subjects we evaluated SARS-CoV-2 spike-specific T and B cell responses, as well as specific IgG, IgM and neutralizing antibodies titres in 22 individuals who received BNT162b2 mRNA COVID-19 vaccine, 11 of which had a previous history of SARS-CoV-2 infection. Evaluations were performed before vaccination and then weekly until 7 days post second injection. Data obtained clearly showed that one vaccine dose is sufficient to increase both cellular and humoral immune response in ex COVID-19 subjects without any additional improvement after the second dose. On the contrary, the second dose is mandatory in naïve ones to further enhance the response. These results question whether a second vaccine jab in ex COVID-19 subjects is required and indicate that millions of vaccine doses may be redirected to naïve individuals, thus shortening the time to reach herd immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence, derived from Ministero dell Istruzione, dell Universita e della Ricerca (Italy) (Project Excellence Departments 2018-2022) and by University of Florence, project RICTD2122.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work has been approved by Careggi ethical committe (Ref. 16859; 19466)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data are included in the manuscript.